Establishing Clinically Relevant Drug Product Specifications (CRDPS): Regulatory Expectations, Approaches, and Data Needed
  • 12:30 PM Eastern
  • Online
  • Register

Establishing clinically relevant drug product specifications (CRDPS) is an important step toward advancing patient-centric drug product development and moving beyond traditional approaches based primarily on manufacturing process capability. By linking critical quality attributes to in vivo drug product performance, CRDPS can help ensure consistent product safety and efficacy while providing opportunities for greater regulatory flexibility throughout the product lifecycle.

This presentation, hosted by the American Association of Pharmaceutical Scientists (AAPS), will provide a regulatory perspective on the scientific considerations, data requirements, and approaches for establishing CRDPS, with particular emphasis on dissolution specifications. Different strategies for linking in-vitro dissolution to in-vivo performance will be discussed, including bracketing approach and physiologically based biopharmaceutics modeling (PBBM). The importance of understanding the impact of critical material attributes (CMAs), critical process parameters (CPPs), and formulation variables on dissolution and drug product performance will also be highlighted.

Building on emerging discussions surrounding the evolution of biopharmaceutics and dissolution testing, the presentation will explore the role of risk-based approaches in guiding dissolution method development, specification setting, and regulatory decision-making. Particular attention will be given to the establishment of dissolution safe space, the use of a totality-of-evidence approach, and the application of predictive biopharmaceutics tools to support specifications that are appropriately aligned with the biopharmaceutical risk of the drug product.

Finally, the presentation will address key scientific and regulatory challenges and highlight the importance of multidisciplinary collaboration among, e.g., CMC, analytical R&D, biopharmaceutics, modeling, and clinical pharmacology experts. Integrating these disciplines can strengthen product understanding.

 

Presenter:

Sandra Suarez-Sharp – Global Head of Regulatory Strategies